Group 1 - The Hong Kong innovative drug industry is experiencing a strong recovery, with significant revenue and profit growth expected in the first half of 2025, driven by accelerated overseas expansion, commercialization, and policy support [1] - The Hong Kong innovative drug index has risen by 108.64% since the beginning of the year, outperforming the Hang Seng Composite Index by 79.70 percentage points, according to Wanlian Securities [1] - Companies with differentiated technology platforms, strong business development (BD) expectations, and those involved in emerging disease areas like Alzheimer's and GLP-1 drugs are recommended for attention in the second half of the year [1] Group 2 - Several innovative drug companies reported impressive mid-year results for 2025, with BeiGene achieving revenue of 17.518 billion yuan, a year-on-year increase of 46.03%, and a net profit of 450 million yuan, compared to a net loss of 2.877 billion yuan in the same period last year [1] - WuXi AppTec in the CXO sector reported a 20.64% year-on-year increase in revenue and a 101.92% increase in net profit attributable to shareholders for the first half of 2025 [1] - Policy changes are expected to further shorten the clinical review and approval times for innovative drugs, enhancing the sector's development [1] Group 3 - As of September 4, 2025, the Hong Kong innovative drug ETF (513120) has seen a decline of 2.70%, while it has increased by 7.80% over the past week [2] - The top ten weighted stocks in the index account for 70.79%, including leading innovative drug companies such as CanSino Biologics, Innovent Biologics, and BeiGene [2] - The latest scale of the Hong Kong innovative drug ETF reached 21.56 billion yuan, marking a new high since its inception, with a net inflow of 32.8559 million yuan [2] Group 4 - The Hong Kong innovative drug ETF (513120) closely tracks the China Securities Hong Kong Innovative Drug Index and allows T+0 trading, enhancing liquidity and capital efficiency for investors [3]

Group 1 - The Hong Kong stock market for innovative drugs opened high but fell, with Zai Lab leading the decline by over 13% and other companies like Innovent Biologics and Ascentage Pharma dropping over 5% [1] - The Hong Kong Stock Connect Innovative Drug ETF (520880) experienced a significant drop of over 4%, with a trading volume of nearly 350 million yuan [1] - The ETF had previously seen four consecutive days of gains, reaching a new closing high [1] Group 2 - The World Lung Cancer Conference (WCLC) will take place from September 6 to 9 in Barcelona, Spain, where Chinese pharmaceutical companies will showcase innovative drug results [3] - Companies such as CanSino Biologics, BeiGene, and Baillie Gifford will present their latest research during the conference [3] - The upcoming conferences and the peak season for licensing agreements with multinational pharmaceutical companies (MNCs) are expected to create a favorable environment for innovative drugs in the coming quarter [3] Group 3 - The Hong Kong Stock Connect Innovative Drug ETF (520880) has shown strong performance, with a year-to-date increase of 118.95%, leading among various innovative drug indices [3][4] - The ETF is set to revise its index compilation rules to exclude companies primarily engaged in CXO services, focusing solely on innovative drug research and development [5] - This revision is expected to enhance the ETF's performance during the upward cycle of the innovative drug industry [5]

Core Insights - As of August 29, 2023, 969 out of 976 comparable ordinary equity funds have reported positive performance in the first eight months of the year, representing a remarkable 99% success rate, with only 7 funds showing declines [1][3]. Fund Performance - The top-performing fund, Huaan Medical Biotechnology Stock A/C, achieved a staggering increase of 107.64% and 107.03%, respectively, making it the only fund to double its value [1][4]. - Other notable funds with over 90% growth include Jiashi Mutual Fund's Jiashi Huirong Selected Stock A/C and Fuguo Medical Innovation Stock A/C, with increases ranging from 91.34% to 98.55% [1][2][5]. Fund Management - The fund managers of the top-performing funds are seasoned professionals with extensive backgrounds in the medical and pharmaceutical sectors. For instance, Jiashi Huirong's manager, Hao Miao, has over 6 years of experience, while Fuguo Medical Innovation's managers, Zhao Wei and Wang Chao, have nearly 8 years of combined experience [2][3]. - Huaan Medical Biotechnology is managed by Sang Xiangyu, who has been with Huaan Fund since 2018 and has a background in investment research [1][2]. Market Trends - The strong performance of A-share markets has contributed to the overall success of equity funds, with only 7 funds reporting declines, the most significant being Minsheng Jianyin's decline of 9.51% [3][4]. - The underperformance of certain funds, such as Qianhai Kaiyuan Traditional Chinese Medicine Stock A/C, which fell by 1.25% and 1.09%, indicates a potential shift in market preferences away from traditional medicine towards innovative pharmaceutical sectors [3][4].

Group 1 - Southbound capital has significantly increased its investment in Hong Kong stocks this year, with a net purchase amount exceeding 1 trillion HKD, surpassing the total net purchase for the entire previous year [1] - From January 1 to September 2, the net purchase amount reached 10,002.21 billion HKD, setting a historical record [1] - There have been 43 trading days this year where the net purchase exceeded 10 billion HKD, with 11 days surpassing 20 billion HKD, including a peak of 35.876 billion HKD on August 5 [1] Group 2 - As of September 2, there are 410 stocks with a southbound capital holding ratio exceeding 10%, 145 stocks exceeding 30%, and 39 stocks exceeding 50% [2] - The top three stocks by holding ratio are China Telecom at 73.99%, Gree Power at 70.03%, and China Shenhua at 67.69% [2] - From 2020 to 2024, the net purchase amounts were 672.1 billion HKD, 454.4 billion HKD, 386.3 billion HKD, 318.8 billion HKD, and 807.869 billion HKD respectively, with a notable increase in 2024 and 2025 [2]

Core Viewpoint - The AI Fund Zhongyin Innovation Medical Mixed A (007718) reported a profit of 1.055 billion yuan for the first half of 2025, with a weighted average profit per fund share of 0.7264 yuan, and a net asset value growth rate of 54.08% [2] Fund Performance - As of September 2, 2025, the fund's unit net value was 2.418 yuan, with a recent three-month net value growth rate of 36.41%, ranking 12 out of 138 comparable funds [5] - The fund's six-month net value growth rate was 73.73%, ranking 8 out of 138, and the one-year growth rate was 105.10%, ranking 7 out of 135 [5] - Over the past three years, the fund's net value growth rate was 83.83%, ranking 2 out of 108 [5] Fund Management Insights - The fund manager, Zheng Ning, oversees four funds, all of which have positive returns over the past year [2] - The fund's management anticipates a moderate economic slowdown in the U.S. with a potential rise in inflation, influenced by tax cuts and regulatory relaxations under uncertain Trump policies [2] Valuation Metrics - As of June 30, 2025, the fund's weighted average price-to-earnings (P/E) ratio was approximately 71.41 times, compared to the industry average of 120.96 times [10] - The weighted average price-to-book (P/B) ratio was about 5.97 times, while the industry average was 4.07 times [10] - The weighted average price-to-sales (P/S) ratio was approximately 10.65 times, against an industry average of 6.52 times [10] Growth Metrics - For the first half of 2025, the fund's weighted average revenue growth rate was 0.11%, and the weighted average net profit growth rate was 29.65% [17] - The weighted annualized return on equity was 0.08% [17] Risk and Return Metrics - As of June 30, 2025, the fund's Sharpe ratio over the past three years was 0.6073, ranking 4 out of 105 comparable funds [25] - The maximum drawdown over the past three years was 40.72%, with the largest quarterly drawdown occurring in Q1 2024 at 27% [27] Fund Composition - As of June 30, 2025, the fund had a total scale of 1.266 billion yuan, with 24,000 holders collectively owning 683 million shares [32][35] - The fund's turnover rate over the last six months was approximately 88.46%, consistently below the industry average for two years [38] - The fund's top ten holdings have consistently exceeded 60% concentration over the past two years, with major stocks including Innovent Biologics, Kelun-Biotech, and Hengrui Medicine [41]

AI基金融通鑫新成长混合A（011403）披露2025年中期报告，上半年基金利润4562.98万元，加权平均基金份额本期利润0.1578元。报告期内，基金净值增长 率为16.86%，截至上半年末，基金规模为4.00亿元。 该基金属于偏股混合型基金，长期投资于医药医疗股票。截至9月2日，单位净值为1.47元。基金经理是万民远，目前管理5只基金近一年均为正收益。其 中，截至9月2日，融通价值成长混合A近一年复权单位净值增长率最高，达73.25%；融通医疗保健行业混合A/B最低，为34.29%。 基金管理人在中期报告中表示，我们依然坚持顺着中国经济转型升级和经济修复的方向寻找投资机会。看好老龄化背景下需求刚性的医药、疫后复苏相关的 消费、以高端制造为代表具备全球竞争优势的出口相关产业和以AI 等为代表的科技进步领域的投资机会。这种机会不仅在A股市场，港股市场同样也有， 尤其是港股市场中很多中国资产价值被严重低估。 截至9月2日，融通鑫新成长混合A近三个月复权单位净值增长率为19.16%，位于同类可比基金100/138；近半年复权单位净值增长率为33.64%，位于同类可 比基金88/138；近一年复权单位净值增长率为 ...

Group 1 - The "Shenzhen-Hong Kong-Guangzhou" innovation cluster has ranked first in the global innovation cluster ranking by WIPO, surpassing the "Tokyo-Yokohama" cluster for the first time in five years [1][5] - The ranking change is attributed to the inclusion of a new key indicator: venture capital (VC) transaction volume, which the "Shenzhen-Hong Kong-Guangzhou" cluster excelled in compared to "Tokyo-Yokohama" [1][6] - The Guangdong-Hong Kong-Macao Greater Bay Area Research Institute emphasizes that the new ranking reflects the increasing importance of financial and talent factors in supporting technological innovation, particularly in emerging industries like artificial intelligence [1][3] Group 2 - The "Shenzhen-Hong Kong-Guangzhou" cluster ranks second globally in PCT international patent applications, with Shenzhen maintaining the highest number of applications in China for 21 consecutive years, reaching 16,300 applications in 2024 [2] - In terms of scientific paper publications, the cluster ranks third globally, with notable contributions from universities in both Shenzhen and Hong Kong [2] - The cluster ranks sixth globally in venture capital indicators, with a VC transaction volume accounting for 2.9% of the global total, compared to 2.2% for the "Tokyo-Yokohama" cluster [5][10] Group 3 - WIPO's methodology for assessing venture capital includes data from startups, unicorns, and other businesses receiving VC funding, highlighting the role of venture capital in transforming technological achievements into marketable products and services [6][7] - The report indicates that venture capital is increasingly vital for supporting technology innovation, especially for early-stage tech companies facing high risks and lacking collateral [7] - Hong Kong's financial ecosystem is thriving, with a significant increase in IPO activities, ranking first globally in IPO fundraising, which enhances the venture capital landscape [7][14] Group 4 - Shenzhen is actively building an international venture capital center, with a significant increase in the number of private equity and venture capital funds, growing by 2.65 times in quantity and 2.25 times in scale since the end of 2018 [8] - Guangzhou has established substantial funds targeting cutting-edge fields like artificial intelligence and biomedicine, with over 270 billion yuan in committed capital for various projects [8] - The "Shenzhen-Hong Kong-Guangzhou" cluster is encouraged to leverage its unique advantages and characteristics, particularly through initiatives like the "QFLP" to facilitate cross-border investment [14][15]

Core Insights - 康方生物 reported a 37.8% year-on-year revenue growth in the first half of 2025, reaching 1.41 billion yuan, with a net loss attributable to shareholders of 570 million yuan, aligning with expectations [1] - The company's product net revenue increased by 49.2% to 1.40 billion yuan, primarily driven by the sales growth of 卡度尼利 and 依沃西纳 after their inclusion in medical insurance [1] - R&D expenses rose by 23.0% to 731 million yuan, while sales expenses increased by 29.8% to 670 million yuan [1] - As of June 30, 2025, the company's cash reserves were approximately 7.14 billion yuan [1] Product Development - The clinical trial for AK112 achieved the overall survival (OS) endpoint, showing statistically and clinically significant OS benefits for patients with EGFR mutation non-squamous NSCLC after progression on EGFR-TKI treatment [2] - AK112 has been approved for one indication and is under review for another, with detailed data expected to be presented at international academic conferences in the second half of 2025 [2] - AK112 is involved in around 30 clinical trials across various indications, including 13 Phase III trials and 6 head-to-head studies, with 4 Phase III trials already yielding positive results [2] - 卡度尼利 (AK104) is undergoing clinical development with three approved indications, including 2L+ CC, 1L CC, and 1L GC, with 2L+ CC included in medical insurance [2] Non-Oncology Pipeline Expansion - The company has received approval for two non-oncology products, including 伊努西单抗 (PCSK9) and 依若奇单抗 (IL-12/IL-23), with additional products under review [3] - The company is accelerating the development of ADC pipelines, with AK138D1 (HER3 ADC) and AK146D1 (Trop2/Nectin4 ADC) currently in global Phase I clinical trials [3] - The earnings per share forecast for 2025 has been adjusted from 0.02 yuan to -0.97 yuan, with subsequent years also revised downwards, while the target price has been raised from 87 HKD to 189 HKD, indicating a 21% upside potential [3]

Investment Rating - The report maintains an "Accumulate" rating for the pharmaceutical and biotechnology sector [8]. Core Viewpoints - The report expresses strong confidence in the innovative drug sector, particularly highlighting the progress of the PD-1/VEGF bispecific antibody drug, Ivosidenib, in its international multicenter Phase III clinical trials for high PD-L1 expressing NSCLC [2][22]. - Ivosidenib has shown significant overall survival (OS) benefits in the HARMONi-A study, confirming its clinical value beyond progression-free survival (PFS) [2][23]. - The report suggests that Ivosidenib's efficacy and safety are consistent across different ethnicities and regions, enhancing its international market potential [2][23]. Summary by Sections Market Review - Last week, the A-share pharmaceutical and biotechnology index fell by 0.65%, underperforming the CSI 300 index by 3.37 percentage points [1][17]. - The Hong Kong Hang Seng Medical Health Index dropped by 3.41%, lagging behind the Hang Seng Index by 1.96 percentage points [1][17]. Company Updates - Recent clinical applications include new undertakings for AK152 injection by Kangfang Biopharma and 9MW3811 injection by Maiwei Biopharma [33]. - Ongoing Phase III clinical trials include HS-20094 by Hansoh Pharmaceutical and TaiTasi by Rongchang Biopharma [33]. Clinical Research Progress - Ivosidenib is expanding its clinical research into various tumor types, including first-line treatments for high-incidence cancers and immune-resistant indications [3][31]. - The report recommends focusing on innovative companies involved in VEGF bispecific antibodies, such as Sanofi, Rongchang Biopharma, Junshi Biosciences, and Innovent Biologics [3]. Investment Strategy for 2025 - The report emphasizes a structural selection of investment opportunities based on payment willingness and ability, focusing on three payment channels: hospital payments, out-of-pocket payments, and overseas payments [3]. - Key recommendations include Heng Rui Medicine, Mindray Medical, United Imaging Healthcare, and Yuyue Medical [3].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康方生物科技（開曼）有限公司 呈交日期: 2025年9月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09926 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊 ...